Published in Leukemia on September 30, 2011
Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway. Leuk Res (2013) 1.60
Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene (2013) 1.20
Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer (2012) 1.17
TPEN induces apoptosis independently of zinc chelator activity in a model of acute lymphoblastic leukemia and ex vivo acute leukemia cells through oxidative stress and mitochondria caspase-3- and AIF-dependent pathways. Oxid Med Cell Longev (2012) 0.94
A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr Hematol Oncol (2014) 0.89
Kaposi's sarcoma-associated herpesvirus-encoded LANA contributes to viral latent replication by activating phosphorylation of survivin. J Virol (2014) 0.82
Inhibitor of apoptosis proteins in pediatric leukemia: molecular pathways and novel approaches to therapy. Front Oncol (2014) 0.80
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. Int J Clin Exp Pathol (2014) 0.79
Localization and upregulation of survivin in cancer health disparities: a clinical perspective. Biologics (2015) 0.79
Targeted nanoparticles for pediatric leukemia therapy. Front Oncol (2014) 0.78
AML sensitivity to YM155 is modulated through AKT and Mcl-1. Cancer Lett (2015) 0.77
YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. J Hematol Oncol (2015) 0.77
Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance. Cell Death Dis (2016) 0.75
Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia. Integr Biol (Camb) (2016) 0.75
CBP/Catenin Antagonists: Targeting LSC's Achilles Heel. Exp Hematol (2017) 0.75
Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma. Oncotarget (2017) 0.75
Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol (2000) 4.27
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res (2008) 3.92
Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem (2000) 3.30
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene (2002) 3.12
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res (2007) 2.80
INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol (2001) 2.62
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest (2004) 2.59
Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell (2002) 2.56
Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood (2000) 2.44
Transcriptional analysis of human survivin gene expression. Biochem J (1999) 2.39
Survivin: a new target for anti-cancer therapy. Cancer Treat Rev (2009) 2.37
Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res (1999) 2.21
Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem (2003) 2.06
RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A (2009) 1.81
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2006) 1.74
Fifty years of studies of the biology and therapy of childhood leukemia. Blood (1997) 1.65
Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun (2004) 1.58
Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol (2001) 1.51
Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene (2004) 1.49
Survivin splice variants regulate the balance between proliferation and cell death. Oncogene (2005) 1.46
Aurora B kinase activation requires survivin priming phosphorylation by PLK1. J Mol Cell Biol (2010) 1.43
Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci (2011) 1.43
DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther (2002) 1.26
Survivin regulates the p53 tumor suppressor gene family. Oncogene (2004) 1.17
Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica (2007) 1.04
Profiling of DNA replication timing in unsynchronized cell populations. Nat Protoc (2006) 1.00
ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression. Pediatr Blood Cancer (2006) 0.88
Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia (1992) 0.86
Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia (1998) 0.85
Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells. J Biol Chem (2009) 0.85
Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 9.78
The myoD gene family: nodal point during specification of the muscle cell lineage. Science (1991) 9.53
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther (2000) 5.09
Presence of an SH2 domain in the actin-binding protein tensin. Science (1991) 4.03
Rates of nucleotide substitution in primates and rodents and the generation-time effect hypothesis. Mol Phylogenet Evol (1996) 3.97
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 3.90
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 3.77
Absence of perilipin results in leanness and reverses obesity in Lepr(db/db) mice. Nat Genet (2000) 3.62
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood (2000) 3.26
Prevention of childhood injuries: evaluation of the Statewide Childhood Injury Prevention Program (SCIPP). Am J Public Health (1989) 3.17
Male-driven evolution of DNA sequences. Nature (1993) 2.86
Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome. Nat Genet (2001) 2.85
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 2.37
The essential mitotic target of calmodulin is the 110-kilodalton component of the spindle pole body in Saccharomyces cerevisiae. Mol Cell Biol (1993) 2.36
Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell (2001) 2.33
STI571: targeting BCR-ABL as therapy for CML. Oncologist (2001) 2.15
High polymorphism at the human melanocortin 1 receptor locus. Genetics (1999) 1.94
Early detection of human immunodeficiency virus on dried blood spot specimens: sensitivity across serial specimens. Women and Infants Transmission Study Group. J Pediatr (1996) 1.79
Chronic myelogenous leukemia. Curr Opin Oncol (2001) 1.78
Chronic myeloid leukemia: current treatment options. Blood (2001) 1.62
Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS (1996) 1.59
Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. Proc Natl Acad Sci U S A (1994) 1.55
Mutation pattern variation among regions of the primate genome. J Mol Evol (1997) 1.53
Protein tyrosine kinases and cancer. Biochim Biophys Acta (1997) 1.52
Ca2+/calmodulin-dependent kinase II mediates simultaneous enhancement of gap-junctional conductance and glutamatergic transmission. Proc Natl Acad Sci U S A (1998) 1.48
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem (1994) 1.43
Microcell mediated chromosome transfer maps the Fanconi anaemia group D gene to chromosome 3p. Nat Genet (1995) 1.43
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia (2007) 1.39
Id: a negative regulator of helix-loop-helix DNA binding proteins. Control of terminal myogenic differentiation. Ann N Y Acad Sci (1990) 1.39
Sex differences in mutation rate in higher primates estimated from AMG intron sequences. J Mol Evol (1997) 1.36
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res (1996) 1.36
The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells. J Immunol (2000) 1.31
VCP, the mammalian homolog of cdc48, is tyrosine phosphorylated in response to T cell antigen receptor activation. EMBO J (1992) 1.30
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia (2011) 1.28
Contrasting rates of nucleotide substitution in the X-linked and Y-linked zinc finger genes. J Mol Evol (1994) 1.28
Delayed replication timing leads to delayed mitotic chromosome condensation and chromosomal instability of chromosome translocations. Proc Natl Acad Sci U S A (2001) 1.26
Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta (2001) 1.24
Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem (1997) 1.23
Spinocerebellar ataxia in a large kindred: age at onset, reproduction, and genetic linkage studies. Neurology (1984) 1.22
Contributors to and mediators of psychological well-being for informal caregivers. J Gerontol B Psychol Sci Soc Sci (1999) 1.22
Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. Blood (1992) 1.21
Identification of ezrin as an 81-kDa tyrosine-phosphorylated protein in T cells. J Immunol (1992) 1.21
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood (2000) 1.20
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia (2008) 1.17
Stimulation through the T cell receptor induces Cbl association with Crk proteins and the guanine nucleotide exchange protein C3G. J Biol Chem (1996) 1.17
The cost of medical care for injuries to children. Ann Emerg Med (1991) 1.16
Biochemical identification of a direct physical interaction between the CD4:p56lck and Ti(TcR)/CD3 complexes. Eur J Immunol (1991) 1.15
The related adhesion focal tyrosine kinase differentially phosphorylates p130Cas and the Cas-like protein, p105HEF1. J Biol Chem (1997) 1.11
The relative contribution of ethnicity versus socioeconomic status in explaining differences in disability and receipt of informal care. J Gerontol B Psychol Sci Soc Sci (1998) 1.10
Apobec-1 and apolipoprotein B mRNA editing. Biochim Biophys Acta (1997) 1.09
Poorer is riskier. Risk Anal (1992) 1.09
Eye examinations for VA patients with diabetes: standardizing performance measures. Int J Qual Health Care (2000) 1.05
pp60src is an endogenous substrate for calpain in human blood platelets. J Biol Chem (1993) 1.05
Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood (1996) 1.05
Self-reported characterization of seventh-grade students' fights. J Adolesc Health (1998) 1.04
Identification of the Src family kinases, Lck and Fgr in platelets. Their tyrosine phosphorylation status and subcellular distribution compared with other Src family members. Arterioscler Thromb Vasc Biol (1997) 1.02
Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene (1994) 1.01
Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia (2004) 1.01
Collagen induces tyrosine phosphorylation of Wiskott-Aldrich syndrome protein in human platelets. Blood (1998) 1.00
A DnaJ protein, apobec-1-binding protein-2, modulates apolipoprotein B mRNA editing. J Biol Chem (2001) 1.00
Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood (1995) 1.00
Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood (1997) 1.00
Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood (1996) 0.99
Chromosomes with delayed replication timing lead to checkpoint activation, delayed recruitment of Aurora B and chromosome instability. Oncogene (2006) 0.98
Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp Hematol (1997) 0.97
Vav binds to several SH2/SH3 containing proteins in activated lymphocytes. Oncogene (1994) 0.97
Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leuk Lymphoma (1997) 0.96
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol (2000) 0.96
Activation of a CrkL-stat5 signaling complex by type I interferons. J Biol Chem (1999) 0.94
Identification in the calcineurin A subunit of the domain that binds the regulatory B subunit. J Biol Chem (1995) 0.94
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells. J Biol Chem (1997) 0.93
e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants? Leukemia (2005) 0.92
Regulation of integrin-mediated p130(Cas) tyrosine phosphorylation in human B cells. A role for p59(Fyn) and SHP2. J Biol Chem (1997) 0.92
p120c-cbl is present in human blood platelets and is differentially involved in signaling by thrombopoietin and thrombin. Blood (1996) 0.92
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia (2008) 0.92
Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins. J Biol Chem (1998) 0.91
Two-hybrid cloning identifies an RNA-binding protein, GRY-RBP, as a component of apobec-1 editosome. Biochem Biophys Res Commun (2001) 0.91
Vaginal colonization or infection with Candida albicans in human immunodeficiency virus-infected women during pregnancy and during the postpartum period. Women and Infants Transmission Study Group. Clin Infect Dis (1997) 0.90
Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood (2000) 0.90
Thrombopoietin and thrombin induce tyrosine phosphorylation of Vav in human blood platelets. Blood (1997) 0.90
STI571: a gene product-targeted therapy for leukemia. Curr Oncol Rep (2001) 0.90
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood (1997) 0.89
Does diagnostic information contribute to predicting functional decline in long-term care? Med Care (2000) 0.89
Potential problems in estimating the male-to-female mutation rate ratio from DNA sequence data. J Mol Evol (1993) 0.89
Functional implications of tyrosine protein phosphorylation in platelets. Simultaneous studies with different agonists and inhibitors. Biochem J (1992) 0.89
The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. Curr Cancer Drug Targets (2001) 0.89
Chronic myelogenous leukaemia--new therapeutic principles. J Intern Med (2001) 0.89
Association of pp60src with Triton X-100-insoluble residue in human blood platelets requires platelet aggregation and actin polymerization. J Biol Chem (1992) 0.88
CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl-expressing cells. Exp Hematol (2000) 0.88
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia (2003) 0.88
Risk adjustment for measuring health outcomes: an application in VA long-term care. Am J Med Qual (2001) 0.88
Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc Natl Acad Sci U S A (1992) 0.88
TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Exp Hematol (2000) 0.88
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation. Exp Hematol (1997) 0.87
The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein. J Biol Chem (1997) 0.86